Lindsay Coleman
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Lindsay Coleman's research focuses on infectious complications and the utilization of intravenous immunoglobulin (IVIG) in patients with relapsed/refractory multiple myeloma treated with teclistamab. This work contributes to understanding treatment-related adverse events in this patient population. Coleman collaborates with researchers at the University of Arkansas for Medical Sciences, including Trilok Shrivastava, Maurizio Zangari, Frits van Rhee, and Asis Shrestha, with whom she has co-authored publications.
Metrics
- Publications: 1
Selected Publications
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
Collaboration Network
Top Collaborators
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Similar Researchers
Based on overlapping research topics